Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integromics Invests in the Optimization of Computing Performance for Bioinformatics Applications

Published: Friday, March 22, 2013
Last Updated: Friday, March 22, 2013
Bookmark and Share
Key collaboration with European experts of HPC to bring new big-data computing solutions into genomics.

Integromics® has announced that it has entered into a consortium for the research on new methods to process quickly and efficiently the large sets of data that are produced in genomics studies, typically based on Next Generation Sequencing technology, and their subsequent application in the early detection of drug reactions and allergies.

Information Technology is intimately coupled to research and modern society, providing solutions, speed and efficiency to perform tasks that until a few decades ago were, in practice, impossible to carry out.

Every day, huge amounts of data are processed by high performance computers and office workstations, and more recently by mobile devices like tablets and smartphones.

This is precisely the reality of genomics research where, for example, the sequence of a single human genome requires about 3 gigabytes (3000 megabytes) of storage.

Following the emergence of these "big" datasets and the need to work with them, experts have begun to think about solutions to optimize the analysis and management of what has been called big-data or macro-data.

The Mr. SymBioMath collaboration, funded with more than 2.6 million euros by the Seventh Framework Programme for R & D of the European Union and coordinated by the Laboratory of Bioinformatics and Information Technology of the University of Malaga-UMA (Spain), has been designed to provide solutions to these needs through the synergy between Integromics (Spain), the Leibniz Supercomputing Centre in Munich-LRZ (Germany), the Johannes Kepler University of Linz-JKU (Austria), RISC Software (Austria) and Carlos Haya Hospital (Spain).

The Mr. SymBioMath project will result in new software applications and data analysis methods to accelerate genomics adoption in the clinical domain.

At the level of computation, the research will be focused on two major challenges: transmission of large volumes of data and optimization of genetic comparison models and visualizations.

JKU will be responsible for creating new models for comparative genomics, evolutionary distances between different organisms, and identification of correlations between genetic variation and phenotypic response of patients to particular treatments.

The supercomputing infrastructure will be provided by the UMA and RISC. They will also develop applications to deliver, collect and display test information.

LRZ will focus on the provisioning of enhanced visualization and Virtual Reality hardware and software for the analysis of the interconnected huge genomic datasets in this project.

The final implementation into commercial software will be done by Integromics.

"Integromics will contribute from a commercial perspective”, said Juan Elvira, CTO of Integromics, “in the design of applications compatible with both computer and tablets-smartphones”.

At the clinical level, Miguel Blanco, Chief of Allergy Carlos Haya Hospital, explained that the project will use data available in the National Allergy Network to validate the software solutions.

The project leader, Dr. Oswaldo Trelles, highlighted that one of the strengths of this study is its focus on medical practice. "The solutions we seek”, he says, “are targeted to a wide range of scientific applications, with personalized medicine certainly being one of them.

Indeed, one of the objectives is to implement applications prototypes applied in real use case scenarios and to evaluate their potential for detecting from genomic data of allergic patients the possible adverse reactions to treatment”.

The Mr. SymBioMath project represents an ideal opportunity for Integromics to reinforce its commitment to the development of software solutions for personalized medicine applied to the clinics.

“This grant and collaboration with renowned computing experts will contribute to the democratization of genomics, in particular through the usage of mobile devices”, said Eduardo González Couto, CSO of Integromics.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Integromics Partners with CITRE and CEIT
Venture attracts EUR 2 million grant for ‘new frontier’ of data interpretation for drug development.
Friday, April 19, 2013
Integromics Partners with FPGMX to Develop Low-Cost Methods for Clinical Genomics
Venture attracts EUR one million grant for ‘new frontier’ of data interpretation for medical usage.
Tuesday, February 07, 2012
Integromics and Ingenuity Expand their Co-operation with the Integration of a Fourth Integromics Product to Ingenuity’s IPA
Combined solutions to offer bridge between discovery and relevance of genomics and proteomics.
Thursday, April 07, 2011
Novel Polyadenylation Genome-wide Profiling Achieved using Next Generation Sequencing Software
A paper published in the journal Cell highlighting a novel genome wide profile of polyadenylation events in human and yeast, performed with Direct RNA Sequencing, demonstrated the importance of appropriate bioinformatics software in maximizing the value of the genomic data.
Monday, January 10, 2011
Integromics and TATAA Biocenter Collaborate to offer Comprehensive qPCR Data Analysis
The TATAA Biocenter is recommending Integromics’ RealTime StatMiner® as a complete solution for qPCR data analysis.
Monday, March 08, 2010
Integromics S.L. Integrates GeneBio’s Phenyx within OmicsHub Proteomics
Geneva Bioinformatics (GeneBio) SA and Integromics S.L. today announced that GeneBio's Phenyx software platform for MS data analysis has been successfully integrated into Integromics’ latest proteomics data analysis and management tool - OmicsHub Proteomics. This integration gives Phenyx and OmicsHub Proteomics users the possibility of combining results from different search engines thereby increasing the accuracy of the protein identification process.
Wednesday, September 23, 2009
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!